Aurora Cannabis has launched a new medical cannabis brand in Germany. The brand is named “Daily Special.” This launch occurred on December 19, 2025. It marks an expansion of Aurora’s offerings in a key European market.
New Brand Aims for Accessibility
The Daily Special brand focuses on providing patients with quality products at affordable prices. This new line features a sativa-dominant cultivar. Its genetics come from Gelonade × Biscotti. The product contains THC levels between 21% and 23%. It has less than 1% CBD. Patients can expect aromas of citrus, sweet earth, and diesel.
Expanding German Market Access
Aurora’s Daily Special is now available. Patients can find it in German pharmacies. It is also accessible via telemedicine platforms. This move highlights Aurora’s commitment to the German medical cannabis sector. Germany is recognized as a vital and growing market for medical cannabis. Aurora aims to strengthen its position in Europe. The company seeks to increase patient choice and affordability.
Aurora’s Growing Presence in Germany
Aurora has a long history in the German market. The company acquired Pedanios GmbH in 2017. This acquisition helped establish Aurora as a major importer and distributor in Europe. Aurora also operates an EU-GMP certified cultivation facility in Leuna, Germany. This facility produces medical cannabis for brands like IndiMed. Aurora is one of only three companies licensed for cannabis cultivation in Germany.
Germany’s Booming Medical Cannabis Landscape
Germany’s medical cannabis market has experienced substantial growth. This surge followed regulatory changes like the Cannabis Act (CanG) in April 2024. Patient numbers have increased dramatically. Annual sales are approaching €1 billion. Telemedicine has been a significant driver of this growth. It expanded access, especially in rural areas. However, discussions about potential telemedicine restrictions are ongoing. Germany is now a leading global benchmark for cannabis policy and commerce.
A Strategic Brand Launch
The launch of Daily Special is significant for Aurora. It expands their product portfolio in one of their fastest-growing markets. Andreas Dotterweich, Senior Vice President of Aurora Europe, stated the launch demonstrates Aurora’s “long-term investment and leadership” in Germany. As a global leader, Aurora is well-positioned to introduce brands that resonate with patients. The company’s extensive genetic library and global portfolio support its market strategy. Aurora consistently aims for pharmaceutical-grade products backed by global GMP standards. This new brand aligns with their mission to provide high-quality cannabis products.
